Panion & BF Biotech Inc (TW:1760) — Stock Price
Panion & BF Biotech Inc (TW:1760) is currently trading at NT$59.30 TWD, up 0.34% today. Over the past 52 weeks, shares have ranged between NT$58.00 and NT$73.20. This page tracks Panion & BF Biotech Inc's live share price on the TW exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see Panion & BF Biotech Inc (1760) market capitalisation.
Panion & BF Biotech Inc (1760) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Panion & BF Biotech Inc's daily closing share price and trading volume on the TW exchange over the past year, giving a clear view of recent price momentum and liquidity.
Panion & BF Biotech Inc Income Statement — Revenue, Profit & Earnings by Year
Panion & BF Biotech Inc's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Revenue | NT$2.03 Billion | NT$1.88 Billion | NT$2.40 Billion | NT$1.90 Billion | NT$1.57 Billion |
| Cost of Revenue | NT$959.37 Million | NT$907.48 Million | NT$1.08 Billion | NT$989.07 Million | NT$754.61 Million |
| Gross Profit | NT$1.07 Billion | NT$974.40 Million | NT$1.32 Billion | NT$912.14 Million | NT$814.03 Million |
| Research & Development | NT$236.88 Million | NT$217.04 Million | NT$248.50 Million | NT$157.71 Million | NT$127.02 Million |
| SG&A | NT$162.00 Million | NT$175.94 Million | NT$233.91 Million | NT$190.32 Million | NT$161.78 Million |
| Total Operating Expenses | NT$855.10 Million | NT$817.57 Million | NT$904.55 Million | NT$744.71 Million | NT$706.09 Million |
| Operating Income | NT$205.67 Million | NT$156.83 Million | NT$341.07 Million | NT$199.42 Million | NT$97.32 Million |
| EBITDA | NT$405.32 Million | NT$327.22 Million | NT$504.62 Million | NT$343.05 Million | NT$181.46 Million |
| EBIT | NT$240.89 Million | NT$156.83 Million | NT$341.07 Million | NT$199.42 Million | NT$97.32 Million |
| Interest Expense | NT$15.02 Million | NT$11.36 Million | NT$7.58 Million | NT$14.68 Million | NT$4.46 Million |
| Income Before Tax | NT$217.44 Million | NT$168.71 Million | NT$333.41 Million | NT$182.65 Million | NT$89.41 Million |
| Income Tax Expense | NT$92.91 Million | NT$91.49 Million | NT$151.06 Million | NT$78.25 Million | NT$61.51 Million |
| Net Income | NT$124.52 Million | NT$77.22 Million | NT$182.34 Million | NT$104.40 Million | NT$27.90 Million |
Panion & BF Biotech Inc Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Panion & BF Biotech Inc's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Assets | NT$3.21 Billion | NT$3.24 Billion | NT$3.09 Billion | NT$2.95 Billion | NT$3.07 Billion |
| Total Current Assets | NT$1.51 Billion | NT$1.48 Billion | NT$1.40 Billion | NT$1.27 Billion | NT$1.45 Billion |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | — | — | — | NT$69.79 Million | NT$96.13 Million |
| Net Receivables | NT$367.89 Million | NT$358.90 Million | NT$355.32 Million | NT$363.50 Million | NT$450.00 Million |
| Inventory | NT$526.93 Million | NT$538.10 Million | NT$545.65 Million | NT$528.52 Million | NT$560.66 Million |
| Property, Plant & Equipment | — | — | — | NT$1.52 Billion | NT$1.41 Billion |
| Goodwill | NT$4.49 Million | NT$4.21 Million | NT$4.21 Million | NT$3.79 Million | NT$3.85 Million |
| Total Liabilities | NT$1.29 Billion | NT$1.32 Billion | NT$1.09 Billion | NT$1.02 Billion | NT$1.83 Billion |
| Total Current Liabilities | NT$1.03 Billion | NT$1.05 Billion | NT$921.58 Million | NT$740.49 Million | NT$946.01 Million |
| Long-term Debt | NT$145.14 Million | NT$125.42 Million | NT$22.90 Million | NT$116.07 Million | NT$669.59 Million |
| Net Debt | NT$146.49 Million | NT$193.21 Million | NT$18.07 Million | NT$223.46 Million | NT$929.21 Million |
| Total Stockholder Equity | NT$1.92 Billion | NT$1.91 Billion | NT$2.01 Billion | NT$1.93 Billion | NT$1.24 Billion |
| Retained Earnings | NT$134.98 Million | NT$80.26 Million | NT$188.50 Million | NT$108.11 Million | NT$27.84 Million |
Panion & BF Biotech Inc Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Panion & BF Biotech Inc generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Cash Flow | NT$351.19 Million | NT$177.42 Million | NT$489.87 Million | NT$401.23 Million | NT$-14.55 Million |
| Capital Expenditures | NT$185.69 Million | NT$181.23 Million | NT$198.64 Million | NT$170.01 Million | NT$101.16 Million |
| Free Cash Flow | NT$165.49 Million | NT$-3.81 Million | NT$291.23 Million | NT$231.22 Million | NT$-115.72 Million |
| Investing Cash Flow | NT$-158.77 Million | NT$-155.27 Million | NT$-144.47 Million | NT$-215.05 Million | NT$-686.61 Million |
| Financing Cash Flow | NT$-170.51 Million | NT$48.67 Million | NT$-167.39 Million | NT$-217.76 Million | NT$643.21 Million |
| Dividends Paid | NT$128.61 Million | NT$171.48 Million | NT$128.61 Million | NT$53.72 Million | NT$138.13 Million |
| Stock-Based Compensation | — | — | NT$0.00 | NT$11.72 Million | NT$0.00 |
| Depreciation | NT$164.42 Million | NT$170.39 Million | NT$163.55 Million | NT$143.62 Million | NT$84.14 Million |
| Change in Cash | NT$23.75 Million | NT$70.37 Million | NT$185.15 Million | NT$-31.01 Million | NT$-54.75 Million |
Panion & BF Biotech Inc Earnings History — EPS Actual vs. Analyst Estimates
Track Panion & BF Biotech Inc's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Mar 02, 2026 | — | — | — |
| Nov 10, 2025 | — | — | — |
| Aug 11, 2025 | — | — | — |
| Apr 30, 2025 | — | — | — |
| Mar 07, 2025 | 0.38 | 0.39 | -2.56% |
| Nov 13, 2024 | 0.32 | 0.37 | -13.51% |
| Aug 13, 2024 | 0.23 | 0.33 | -30.30% |
| Mar 07, 2024 | 0.35 | 1.10 | -68.18% |